These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 27709452)

  • 21. Biosimilars: Key regulatory considerations and similarity assessment tools.
    Kirchhoff CF; Wang XM; Conlon HD; Anderson S; Ryan AM; Bose A
    Biotechnol Bioeng; 2017 Dec; 114(12):2696-2705. PubMed ID: 28842986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PDA Biosimilars Workshop Report (September 27-28, 2018)-Getting It Right the First Time for Biosimilar Marketing Applications.
    Krause S; Lacana E; Welch J; Shapiro M; Downey C; Chung J; Zhou Q; Van Der Plas M; Depatie C; Ingram B; Srebalus-Barnes C; Polozova A; Rellahan B; Choi D; Burdick R; Stangler T; Shacter E
    PDA J Pharm Sci Technol; 2019; 73(4):401-416. PubMed ID: 31004040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. On sample size requirement for analytical similarity assessment.
    Zhao Y; Chang YW; Chow SC
    J Biopharm Stat; 2018; 28(6):1143-1159. PubMed ID: 29513612
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FDA's Approach to Regulating Biosimilars.
    Lemery SJ; Ricci MS; Keegan P; McKee AE; Pazdur R
    Clin Cancer Res; 2017 Apr; 23(8):1882-1885. PubMed ID: 28034906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The US approach to biosimilars: the long-awaited FDA approval pathway.
    Calvo B; Zuñiga L
    BioDrugs; 2012 Dec; 26(6):357-61. PubMed ID: 23030677
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pragmatic rules for comparability of biological medicinal products.
    van der Plas RM; Hoefnagel MHN; Hillege HL; Roes KCB
    Biologicals; 2020 Jan; 63():97-100. PubMed ID: 31836276
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reporting of quality attributes in scientific publications presenting biosimilarity assessments of (intended) biosimilars: a systematic literature review.
    Alsamil AM; Giezen TJ; Egberts TC; Leufkens HG; Vulto AG; van der Plas MR; Gardarsdottir H
    Eur J Pharm Sci; 2020 Nov; 154():105501. PubMed ID: 32739253
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rational Selection, Criticality Assessment, and Tiering of Quality Attributes and Test Methods for Analytical Similarity Evaluation of Biosimilars.
    Vandekerckhove K; Seidl A; Gutka H; Kumar M; Gratzl G; Keire D; Coffey T; Kuehne H
    AAPS J; 2018 May; 20(4):68. PubMed ID: 29748754
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessing analytical comparability of biosimilars: GCSF as a case study.
    Nupur N; Singh SK; Narula G; Rathore AS
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Oct; 1032():165-171. PubMed ID: 27289250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biosimilars: the paradox of sharing the same pharmacological action without full chemical identity.
    Pani L; Montilla S; Pimpinella G; Bertini Malgarini R
    Expert Opin Biol Ther; 2013 Oct; 13(10):1343-6. PubMed ID: 23805906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. On the glycosylation aspects of biosimilarity.
    Hajba L; Szekrényes Á; Borza B; Guttman A
    Drug Discov Today; 2018 Mar; 23(3):616-625. PubMed ID: 29337201
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Considerations in the early development of biosimilar products.
    Li EC; Abbas R; Jacobs IA; Yin D
    Drug Discov Today; 2015 May; 20 Suppl 2():1-9. PubMed ID: 25572407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparability and biosimilarity: considerations for the healthcare provider.
    Lee JF; Litten JB; Grampp G
    Curr Med Res Opin; 2012 Jun; 28(6):1053-8. PubMed ID: 22519391
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Statistical considerations in biosimilar clinical efficacy trials with asymmetrical margins.
    Li Y; Liu Q; Wood P; Johri A
    Stat Med; 2013 Feb; 32(3):393-405. PubMed ID: 22991275
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biosimilar monoclonal antibodies: preclinical and clinical development aspects.
    Gonçalves J; Araújo F; Cutolo M; Fonseca JE
    Clin Exp Rheumatol; 2016; 34(4):698-705. PubMed ID: 27383278
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biosimilar safety factors in clinical practice.
    Reinisch W; Smolen J
    Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S9-15. PubMed ID: 26058551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hydrophilic Interaction Chromatography Hyphenated with Mass Spectrometry: A Powerful Analytical Tool for the Comparison of Originator and Biosimilar Therapeutic Monoclonal Antibodies at the Middle-up Level of Analysis.
    D'Atri V; Fekete S; Beck A; Lauber M; Guillarme D
    Anal Chem; 2017 Feb; 89(3):2086-2092. PubMed ID: 28208257
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Scientific and statistical considerations in evaluating the analytical similarity of ABP 501 to adalimumab.
    Sivendran R; Ramírez J; Ramchandani M; Liu J
    Immunotherapy; 2018 Aug; 10(11):1011-1021. PubMed ID: 30071739
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An Integrated Approach for a Structural and Functional Evaluation of Biosimilars: Implications for Erythropoietin.
    Gianoncelli A; Bonini SA; Bertuzzi M; Guarienti M; Vezzoli S; Kumar R; Delbarba A; Mastinu A; Sigala S; Spano P; Pani L; Pecorelli S; Memo M
    BioDrugs; 2015 Aug; 29(4):285-300. PubMed ID: 26334631
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Novel Bootstrapping Test for Analytical Biosimilarity.
    Zahel T
    AAPS J; 2022 Oct; 24(6):112. PubMed ID: 36271265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.